Nih scientists have a break. Discharges delay it.

Scientists from the National Institutes of Health showed a promising step to combat a person’s own immune cells to combat gastrointestinal cancer in a paper in Nature Medicine on Tuesday. On the same day, the agency was hit with devastating layoffs that many NIH employees had in tears in tears.

The treatment approach is still at the beginning of its development; The personalized immunotherapy regime shrank in just about a quarter of patients with colon, rectal and other GI cancer, which were recorded in a clinical study. A researcher who was not involved in the study described the results as “remarkable” because it highlighted a way to a frustratingly difficult goal in medicine – and used a person’s own immune defense to aim at solid tumor cancer.

Subscribe to the Post newsletter for the most important and interesting stories from the Washington Post.

So far, cell-based immunotherapy has mainly worked on blood cancer such as leukemia, but not on the firm cancer that have seed tumors in the chest, brain, lungs, pancreas and GI-tracts.

“I think that’s a very exciting study,” said Patrick HWU, President of the Moffitt Cancer Center in Tampa, Florida. “There is still a lot to do … but that’s a really great start in the right direction.”

However, progress comes at a sad time for science – and for patients, said the head of work, Nih -immunotherapy Pionier Steven Rosenberg.

Two patient treatments using experimental therapy had to be delayed, since NIH’s ability to produce personalized cell therapies, to redeem highly qualified employees and to slow down by buying slowdowns. These occurred before major layoffs on Tuesday.

The quality of the supply in the NIH Clinical Center, the country’s largest research hospital, is still excellent, said Rosenberg. However, the government’s aggressive reduction in employees and the government’s disability begins to delay this care.

“Everything I try to do, I try to do with warp speed. These are people with desperate diseases and nowhere,” said Rosenberg. “At the moment it would take a month if things don’t make things worse, it would be a month [delay]. These are not patients who still have many months. “

Natalie Phelps from Bainbridge Island, Washington, is one of those who cannot expect it. The 43-year-old mother of two children learned five years ago that GI symptoms that their doctors had attributed to their second pregnancy were actually caused by colon cancer.

Since then, Phelps has had an 18 -hour operation through “pretty hell I can go through” to remove her initial tumor, radiation into her brain, three liver operations and 48 round chemotherapy. Nevertheless, the cancer spread through her body.

This autumn she had hope when she arrived at the NIH Clinical Center in Bethesda, Maryland for two days, to determine whether she qualified for one of Rosenberg’s attempts. It was amazed at the quality of medical care and the efficiency of work.

“When I was invited to only be shown, I was overjoyed. I felt like I had won the jackpot,” said Phelps. “When I went into the NIH … it only made me so proud – it was a beautiful building and everything was managed so professionally and efficiently, in a way that I had not experienced in any health care all over the country.”

HHS replied to an e -mail in which they were asked with an explanation of clinical trial delays: “Nih and HHS meet the executive ordinance of President Trump.”

– – – –

Progress built over years

For decades, scientists have dreamed of using the patient’s own immune cells to attack cancer. Rosenberg has long been a leader in this area, at the top of medicine.

In 2017, the first medicine was in a transformative new medical class – one based on immune cells that were harvested and genetically processed from the blood of patients to aim for cancer cells to treat blood cancer.

Last year, a different type of cell -based immunotherapy was approved for melanomas that spread to other parts of the body or resisted other forms of treatment. Instead of constructing the cells, harvesting and expanded scientists the Tils -as Tils mentioned by patients, which are called Tils for Tumor -infiltratting -Lymphocytes. These cells are usually present, but not in sufficient large enough to slow the cancer.

Rosenberg’s work has driven both approaches to cancer therapy forward. Despite the progress, it was a great scientific challenge to find ways to agree to this cell-based immunotherapy approach for frequent solid tumors that cause the vast majority of cancer deaths.

“Research work is very rare in a straight line – they have ideas, they pursue them, most things don’t work, some things work. They build on them,” said Rosenberg.

That happened in the new study. Rosenberg and colleagues initially tried to create Tils with the method that was spread out in the melanoma for 18 patients with GI cancer. It failed completely.

In a second iteration, his team seized the mutations existing in the tumor of each patient and used this information to find out and expand the tils in which the specific tumor cells could go home. The results were far from a triumph, but provided a hint – this time three out of 39 tumors of the patients shrank.

In the last phase of the study, the scientists added a medication called Pembrolizumab to take the brakes of immune cells. This time, eight of the 34 patients answered.

“At the moment, only a few laboratories in the country can do what they have just done,” said HWU.

– – – –

Patients who cannot wait for progress

Rosenberg is already working on refining and improving the results. But he said that in his many decades he has never seen anything like the turbulence outside of his laboratory, it begins to influence science.

Two scientists who were involved in the specialized process of producing cells for patient treatment were fired in the test flushing. Nine highly qualified scientists in his team have appointments that have to be renewed in 2025 or early 2026 without being sure.

“If this is not the case, it will reset more,” said Rosenberg. “We had to slow down our work and delay the treatment of some patients.”

There are even more minor restrictions. Travel is restricted by an administrative regulation, so Rosenberg could not take part in a meeting of the Society of Surgical Oncology, in which doctors and scientists exchange ideas that drive cancer.

According to the probationists, the number of people who can buy essential for research has dropped, which it has more slowly and more difficult to get supplies. Rosenberg is now concerned that the massive reduction in violence in the past week makes the process even arbitrary.

When Phelps went to Nih, she told her young children that she would visit the best doctors in the country to see if they had a solution. These doctors told her that she was a good candidate for the Til attempt with a restriction – she had to wait until one of the many tiny tumors in her body got big enough to meet the minimum size criteria.

She went home, where she waited anxiously that her tumors grow big enough to qualify for the attempt. Now she has a new source of fear: the changes that the new administration has imposed have subdued their hope of the future.

“It’s one thing that seems unfair: Why should a metastatic cancer patient need more stress?” Said Phelps. “Why slow research when the cancer rates increase, especially among young people under 50?”